Thesan Pharmaceuticals, a Carlsbad CA-based developer of novel approaches for the treatment of dermatological disorders, closed a $49m Series B financing.
The round was led by current investor Novo Ventures with participation from SV Life Sciences, Lundbeckfond Ventures and Novartis Venture Fund. In conjunction with the financing, Michael Ross from SVLS and Mette Kirstine Agger from Lundbeckfond Ventures will join the company’s board.
Led by J. Gordon Foulkes, Ph.D., Chief Executive Officer, Thesan Pharmaceuticals a biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions, including acne and atopic dermatitis.
The company intends to use the funds develop new candidates in this area.